UK MHRA began rolling review of Moderna’s mRNA COVID-19 vaccine
On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
-
Moderna announced supply agreement with Qatar for mRNA vaccine against COVID-19
On Oct. 26, 2020, Moderna announced a supply agreement with the Ministry of Public Health of Qatar for…
-
Todos Medical announced instrument validation completed at MOTO+PARA Mobile Lab
On Oct. 26, 2020, Todos Medical announced the completion of the instrument validation in its mobile lab division….
-
Roche announced collaboration with Atea Pharmaceuticals to develop potential oral treatment for COVID-19 patients
On Oct. 22, 2020, Roche and Atea Pharmaceuticals announced they had joined forces in the fight against COVID-19…
-
Amyris and the Infectious Disease Research Institute entered into exclusive license for novel RNA vaccine platform
On Oct. 22, 2020, Amyris and the Infectious Disease Research Institute (IDRI) announced the signing of a Collaboration…
-
Moderna completed enrollment of phase 3 COVE study of mRNA vaccine against COVID-19
On Oct. 22, 2020, Moderna announced that it had completed enrollment of 30,000 participants for the Phase 3…
-
RNA ‘ticker tape’ records gene activity over time
On Oct. 19, 2020, researchers at MIT, Harvard, and the Broad Institute of MIT announced they had developed…
-
Moderna received confirmation of eligibility for submission of MAA to the European Medicines Agency for COVID-19 vaccine
On Oct. 14, 2020, the European Medicines Agency (EMA) announced it had received an application for conditional marketing…
-
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
-
Moderna announced initiation of rolling submission to Health Canada for mRNA vaccine against COVID-19
On Oct. 13, 2020, Moderna announced initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s…
-
LabCorp COVID-19 molecular test innovation received FDA authorization
On Oct. 2, 2020, LabCorp announced that it had received an Emergency Use Authorization (EUA) from the U.S….
-
BioNTech and Pfizer announced Nature publication of German phase 1/2 study data from mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2…
-
Investigational COVID-19 vaccine well tolerated and generated iImmune response in older adults
On Sept. 29, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that a phase 1…
-
Moderna announced publication in The NEJM of interim results from phase 1 study of its mRNA vaccine against COVID-19
On Sept. 29, 2020, Moderna announced the publication of the second interim analysis of the open-label Phase 1…
-
COVID-19 vaccine generated immune response in older adults
On Sept. 29, 2020, a phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection was…
-
Evaluation of LamPORE rapid tests for Covid-19 showed high levels of diagnostic sensitivity
On Sept. 25, 2020, scientists from the University of Oxford’s Nuffield Department of Medicine published their evaluation of…
-
Pfizer and BioNTech announced data from preclinical studies of mRNA-based vaccine candidate against COVID-19
On Sept. 9, 2020, Pfizer and BioNTech announced preliminary preclinical data in mouse and non-human primate models from…
-
COVID-19 | FDA | HIV | Infectious Disease | Vaccine
Pfizer and BioNTech to potentially supply EU with 200 million doses of mRNA-based vaccine candidate against SARS-CoV-2
On Sept. 9, 2020, Pfizer and BioNTech announced that they had concluded exploratory talks with the European Commission…
-
OraSure’s ORAcollect-RNA device Included in EUA granted to MiraDx for SARS-CoV-2 test
On Sept. 3, 2020, OraSure Technologies announced that its ORAcollect-ﾷRNA (OR-100) collection device was included along with other…
-
Disease | NIH | Therapeutics
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
-
AIM ImmunoTech decreased SARS-CoV-2 infectious viral yields by 90% using new in vitro model
On Aug. 27, 2020, AIM ImmunoTech announced that it had identified an effective in vitro model at The…
-
Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…
-
Sorrento announced agreement to acquire SmartPharm and develop gene-encoded therapeutic antibodies for COVID-19 and cancer therapeutics
On Aug. 20, 2020, Sorrento Therapeutics and SmartPharm Therapeutics announced the signing of a merger agreement under which…
-
Pfizer and BioNTech shared positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19
On Aug. 20, 2020, Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their U.S….
-
Bio-Techne and Leica Biosystems are acceleratied disease research with RNAscope COVID-19 probes and the BOND RX
On Aug. 19, 2020, Bio-Techne in partnership with Leica Biosystems, announced the automation of RNAscope COVID-19 probes on…
-
Moderna announced supply agreement with U.S. Government for initial 100 million doses of mRNA vaccine against COVID-19
On Aug. 11, 2020, Moderna announced that the U.S. government has secured 100 million doses of mRNA-1273 as…
-
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
-
Pfizer and BioNTech announced an agreement with the MHLW in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate
On Jul. 31, 2020, Pfizer and BioNTech announced an agreement with the Ministry of Health, Labour and Welfare…
-
Veracyte and MAVIDx announcd agreement for MAVIDx to develop ultra-high volume COVID-19 testing on the nCounter System
On Jul. 29, 2020, Veracyte and MAVIDx announced an agreement for MAVIDx to develop ultra-high throughput genomic testing…
-
FDA authorized Quest Diagnostics lab method designed to increase COVID-19 molecular diagnostics capacity
On Jul. 29, 2020, Quest Diagnostics announced that the U.S. Food and Drug Administration (FDA) has granted emergency use…
